WVE WAVE Life Sciences

Wave Life Sciences to Webcast Conference Call of First Quarter 2020 Financial Results on May 11, 2020

Wave Life Sciences to Webcast Conference Call of First Quarter 2020 Financial Results on May 11, 2020

CAMBRIDGE, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference call at 8:30 a.m. ET on Monday, May 11, 2020, to discuss its first quarter 2020 financial results and provide a business update.

The webcast of the conference call may be accessed by visiting the “Events” section in the Investor Relations page of the Wave Life Sciences website at . The live teleconference may be accessed by dialing (866) 220-8068 (domestic) or (470) 495-9153 (international) and entering conference ID: 5669348. Following the conference call, an archived version of the call will be available on the website. 

About Wave Life Sciences

Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit and follow Wave on Twitter @WaveLifeSci.

Investor Contact:

Kate Rausch

617-949-4827

  

Media Contact:

Alicia Suter

617-949-4817

 

EN
29/04/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on WAVE Life Sciences

David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
 PRESS RELEASE

Wave Life Sciences Reports Second Quarter 2025 Financial Results and P...

Wave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update WVE-006, the leading GalNAc-RNA editing oligonucleotide designed to correct AAT protein and address both lung and liver manifestations of AATD, rapidly advancing in RestorAATion-2 study of AATD patients; multi-dosing is complete in first cohort (200 mg) and single dosing is complete in second cohort (400 mg) RestorAATion-2 clinical data from complete 200 mg single and multidose dose cohorts remain on track for 3Q 2025; data from complete 400 mg single dose cohort remain on track for fall 2025 ...

Yun Zhong
  • Yun Zhong

AATD Multi-Dose Data Should Be Good; Could Be Available Soon

Initial INHBE data in 2H25 Will be the Next Catalyst. WVE expects to report safety and tolerability, as well as biomarker data that could reflect healthy weight loss from the placebo-controlled study (NCT06842186). We would expect positive stock reaction if the data show dose-dependent knockdown of

ResearchPool Subscriptions

Get the most out of your insights

Get in touch